It addresses the need for a cost-effective non-invasive assay for diagnosis and surveillance of bladder cancer. It is based on a clinically validated signature of ten differentially-expressed genes and displays superior performance (sensitivity 80%; specificity 94%; AUC 0.91) to other molecular markers in the market. The validation study also demonstrated the excellent performance of additional of 2, 5 and 12-gene panels.
Bladder cancer is among the five most common malignancies worldwide being responsible for 3% of all cancer deaths in males and 1% in females. If detected early, 5-year survival is high (94%), but >70% of diagnosed patients will relapse within this period, with 20% progressing to muscle invasive cancer (T2 or higher). High prevalence, survival and relapse rates combine to make BC one of the most expensive cancers to treat and monitor.
The gold standard diagnostic tool is combined cystoscopy and cytology which is costly and highly invasive requiring transurethral access and presenting the risk of important complications and discomfort to patients. Because clinical symptoms are not useful in predicting progression, surveillance requires frequent cystoscopies, on average in excess of 13 per patient following initial diagnosis and treatment.
A clear opportunity exists to replace suveillance, and eventually initail examinations, with a cost-effective and non-invasive procedure.
The current assay is based on a validated panel of 10 differentially expressed genes employing RT-qPCR on spontaneous urine samples [1-4].
Clinical results on 525 patients after a prospective multinational validation demonstrated that our single non-invasive test yields 80% sensitivity and 94% specificity vs. 80% sensitivity and 90% specificity for combined invasive and costlier cystoscopy and cytology . This performance is superior to that of competing biomarkers in the market (NMP22, Alere or BTA Stat, Polymedco) as well as being significantly cheaper than FISH-based tests (UroVysion, Abbott).
Biofina Diagnostics holds the commercial exploitation rights of the patent families protecting the diagnostic method. The first one has been granted in the EU, USA, Canada and Japan. Additional gene-signatures have been claimed in a new EU patent application filed in January 2013 that entered the PCT phase in January 2014 and Regional phases in August 2015 (See IP status below).
Biofina Diagnostics S.L. is currently seeking a licensing/distribution partner with capacity to support the company in taking this assay into the market.
© 2013 Fina Biotech. Madrid. Tel +34 917 991 564 email@example.com